<DOC>
	<DOCNO>NCT00247494</DOCNO>
	<brief_summary>This study substudy MAN2 -study ( Mycophenol mofetil Antiretroviral Naïve patient 2 , see elsewhere ClinicalTrials.gov database ) . In MAN2 study , HIV-1 infect patient treated antiretroviral treatment randomize treatment Mycophenol mofetil ( MMF ) 500 mg BID control group without treatment ( open label ) . Both patient randomize treatment MMF patient randomize control group ask participate also substudy . In substudy want show whether monotherapy Mycophenol mofetil ( MMF ) patient infect HIV-1 reduce acceleration atherogenesis attenuate various inflammatory pathway normally involved progression atherosclerosis .</brief_summary>
	<brief_title>Effects Mycophenolate Mofetil ( MMF ) Surrogate Markers Cardiovascular Disease HIV-1 Infected Patients</brief_title>
	<detailed_description>- background Immune activation play important role atherogenesis . In HIV-1 infection , immune system chronically hyperactivated . There also seem increased incidence cardiovascular disease untreated HIV-1 infection . Mycophenol mofetil ( MMF ) use treat immune activation untreated HIV-1 infected patient MAN2-study ( see elsewhere ClinicalTrials.gov database ) . - Hypothesis T-cell inhibition MMF attenuate T-cell number , T-cell activation T-cell - monocyte interaction , thereby minimize T-cell-driven inflammatory amplification loop . In addition , MMF reduce expression adhesion molecules endothelial cell leucocytes , thereby attenuate recruitment circulate leucocyte atherosclerotic plaque . Combining effect MMF treatment improve anti-atherogenic defence mechanism , improvement endothelial function attenuation pro-inflammatory state . *design This substudy multi-center , double-blind , randomize , trial `` Mycophenol mofetil Antiretroviral Naïve patient 2 ( MAN2 study ) '' ( call main study hereafter ) . The aim substudy evaluate effect mycophenolate mofetil ´surrogate markers´ atherosclerosis group HIV-1 infect patient . All 90 patient include main study ask participate substudy . A separate inform consent need . Patients participate substudy undergo study procedure substudy day 0 week 48 main study ( i.e . first dose MMF 48 week MMF treatment patient randomize MMF treatment ) . Extra blood drawn measure several biochemical marker associate atherosclerosis measure . Furthermore measurement condition blood vessel perform ( use ultrasound , amongst others ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Any patient include MAN2study van enter substudy ( see protocol MAN2 study ) Any condition , illness use medication accord investigator compatible conduct substudy could interfere evaluation require study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>immunomodulation</keyword>
</DOC>